


# Luseogliflozin effective for T2DM with low-carb, high-carb diet

December 29 2016

---



(HealthDay)—For patients with type 2 diabetes (T2D), the SGLT2

inhibitor luseogliflozin has similar efficacy when meals contain 40 to 55 percent total energy from carbohydrate (TEC), according to a study published online Dec. 19 in *Diabetes, Obesity and Metabolism*.

Daisuke Yabe, M.D., Ph.D., from the Kansai Electric Power Research Institute in Kobe, Japan, and colleagues examined the safety and efficacy of luseogliflozin under differing [carbohydrate intake](#) in Japanese individuals with T2D. Participants were randomized to [carbohydrate](#)-adjusted meals for 14 days: [high carbohydrate](#) (HC; 55 percent TEC)-high glycemic index (HGI), HC-low glycemic index (LGI), and low carbohydrate (LC; 40 percent TEC)-HGI. Participants had received luseogliflozin for the past seven days and underwent continuous glucose monitoring (CGM) before and after luseogliflozin treatment.

The researchers found that in all three groups, luseogliflozin significantly decreased the area under the curve and mean CGM values to a similar extent. At all time points, fasting plasma glucose, insulin, and glucagon were similar. On day 15, ketone bodies were significantly increased in LC-HGI versus HC-HGI and HC-LGI.

"In conclusion, luseogliflozin has similar efficacy and safety in Japanese T2D individuals when [meals](#) contain 40 to 55 percent TEC, but a strict low-carbohydrate diet on this class of drug should be avoided to prevent SGLT2 inhibitor-associated diabetic ketoacidosis," the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including Taisho Toyama, which manufactures luseogliflozin and funded the trial.

**More information:** [Full Text \(subscription or payment may be required\)](#)

Copyright © 2016 [HealthDay](#). All rights reserved.

Citation: Luseogliflozin effective for T2DM with low-carb, high-carb diet (2016, December 29)  
retrieved 5 May 2024 from

<https://medicalxpress.com/news/2016-12-luseogliflozin-effective-t2dm-low-carb-high-carb.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--